New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLeuprolide vs Palmitoyl Tetrapeptide-7

Leuprolide vs Palmitoyl Tetrapeptide-7

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Leuprolide
Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Summary
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Half-Life
~3 hours (SC/IM), but depot formulations last 1–12 months
Topical penetration-dependent; effects last hours to days
Admin Route
SubQ, IM
Topical
Research
Typical Dose
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
2-5 ppm concentration in formulation
Frequency
Per depot schedule
Twice daily
Key Benefits
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
Side Effects
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
Stacks With